about
Increased responsiveness of human coronary artery endothelial cells in inflammation and coagulationAdiponectin is an endogenous anti-fibrotic mediator and therapeutic target.Uropathogenic Escherichia coli induces serum amyloid a in mice following urinary tract and systemic inoculation.Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.Comparison and evaluation of different methodologies and tests for detection of anti-dsDNA antibodies on 889 Slovenian patients' and blood donors' seraLevels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?Improved Protective Effect of Umbilical Cord Stem Cell Transplantation on Cisplatin-Induced Kidney Injury in Mice Pretreated with Antithymocyte GlobulinMetabolic fingerprints of human primary endothelial and fibroblast cellsTenascin-C drives persistence of organ fibrosis.Uteroglobin, a possible ligand of the lipoxin receptor inhibits serum amyloid A-driven inflammation.AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.Could antibodies against serum amyloid A function as physiological regulators in humans?A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods.Serum amyloid A activation of human coronary artery endothelial cells exhibits a neutrophil promoting molecular profile.Correlation Between Mitochondrial DNA Content Measured in Myocardium and Peripheral Blood of Patients with Non-Ischemic Heart Failure.Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa.A study of extracellular vesicle concentration in active diabetic Charcot neuroarthropathy.Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A.An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosisInterleukin-1β Induces Intracellular Serum Amyloid A1 Expression in Human Coronary Artery Endothelial Cells and Promotes its Intercellular ExchangeClinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISAGene and miRNA expression in giant cell arteritis-a concise systematic review of significantly modified studiesInsight into inflammatory cell and cytokine profiles in adult IgA vasculitisNeutralizing effects of anti-infliximab antibodies on synergistically-stimulated human coronary artery endothelial cellsUtility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patientsShort lymphocyte, but not granulocyte, telomere length in a subset of patients with systemic sclerosisAutoantibodies against dsDNA measured with nonradioactive Farr assay-an alternative for routine laboratoriesThe immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective studyOlive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial CellsHyperspectral evaluation of peritoneal fibrosis in mouse modelsEvaluating the utility of autoantibodies for disease activity and relapse in giant cell arteritis
P50
Q33606612-CD99220E-1381-4FCD-8B95-DF8860A36D3BQ33860888-71CEFB5B-65DA-4F79-90D4-706286972BE7Q34200173-16791700-2269-4C33-A105-D864AF010A02Q35064030-5D49A0B5-964F-4134-A223-A4AB1B6B9D61Q35625532-1C8C8E2D-1B0E-4E3C-80EC-B6D8CE93E2B1Q36245922-7B8CCB59-551F-4090-BBF6-1E334A395C47Q36530432-E1B26DE8-761D-4795-9ED2-B6CE9A977828Q36952522-7DB91165-3E7D-4111-909A-6030D0217EC9Q36975903-101F9AF3-5FF8-4734-8C39-2CA8AF81A194Q37693893-31D73B3F-2055-4F84-A0D7-77B1DAE21094Q44060791-130ED620-8575-4D34-B66B-905DE3049C30Q45349906-0DD3A9CA-3321-4F6C-9DE3-A7D19D4F556AQ47340698-28DA10E2-B7C5-4FE8-B23F-795C420CE4CAQ47795714-D33CC564-8451-452F-9174-ED8CC30DA069Q50222757-ABD4BD9C-AC25-4AE6-A6F2-3C19549DD1A5Q50558085-B2F93080-2D0C-4D4E-915B-022FEF613D04Q50582667-4A775CD4-98A2-47B9-A8A0-1B4193ABBDF4Q53695989-30511CBB-FFA3-41D1-9C5D-ADEAD2F2BE2CQ55008598-A08A4ED7-A666-45FB-9BD2-3BBF71DA709AQ58797878-BE07C687-2540-48E9-ACA4-8A64AF27313CQ90220301-3A1DF0DC-45DC-4E36-A364-9C92636351EEQ90265650-4E5779A2-8E2D-42A2-AAB8-74135C5F7CE0Q90704471-FE22CCCE-FA8D-47FB-A9A5-B93CCC6B610FQ90729225-1ACC1B16-9DBF-408B-89BD-8BA8707C07C9Q90823187-5192AF34-0CA7-419C-85C6-C4C56CF0C2D2Q91134883-CDB03569-D13F-4026-BD16-9D232C3A77F8Q91209280-9319AFA6-8A3D-46B2-913D-563D7B31370DQ91376588-A22A9662-27C0-4D81-8E63-CE6FE04E9368Q91563190-B6774895-026C-4A2C-B4EE-BEE2F9B789E8Q92482425-B8B40635-37FE-4274-AA7D-317B1A7C5903Q93272476-A027CBC0-FD06-42D2-8D96-A81993A0A188Q95523177-CE78FB52-807E-4A74-ABB6-92518439F51E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Katja Lakota
@en
Katja Lakota
@nl
type
label
Katja Lakota
@en
Katja Lakota
@nl
prefLabel
Katja Lakota
@en
Katja Lakota
@nl
P31
P496
0000-0002-8062-7908